Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences and increased the price target to $115.00 from $110.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tyler Van Buren has given his Buy rating due to a combination of factors including Gilead Sciences’ strong financial performance and positive future outlook. The company reported a notable 3% earnings per share (EPS) beat, primarily driven by higher-than-expected sales in its HIV segment, which were 5% above consensus estimates. This was complemented by an increase in EPS guidance by $0.20 at the midpoint, reflecting management’s confidence in sustained growth.
Additionally, Gilead’s total revenue surpassed expectations, with product sales excluding Veklury showing a 9% increase. The company also raised its 2025 guidance, projecting a 3% year-over-year growth in HIV sales, which is a positive indicator for future earnings. Despite some declines in other areas such as cell therapy and liver disease, the overall financial health and strategic initiatives, including the anticipated launch of Yeztugo and upcoming Phase III HIV readouts, support the Buy rating.
In another report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $128.00 price target.